A New Treatment for Keratoconus: Lab-Made Hydrogel Implant Could Restore Vision

Why It Matters

A donor‑independent, mass‑produced corneal implant could dramatically expand access to sight‑restoring treatment for keratoconus patients worldwide, reducing costs and alleviating the chronic transplant shortage.

Key Takeaways

• Synthetic hydrogel implant targets advanced keratoconus without donor tissue
• Lab-made corneal material mimics natural cornea’s functional properties
• Successful animal trials show laser insertion and stable unfolding
• ETH Zurich team aims for pilot human study to prove safety
• Scalable production could lower costs and treat millions globally

Summary

A team at ETH Zurich has unveiled a lab‑made hydrogel corneal implant designed to treat advanced keratoconus, a progressive thinning disease that currently forces most patients to await scarce donor tissue.

The synthetic gel replicates the biomechanical and optical properties of the native cornea, allowing it to be inserted via a standard laser procedure, unfold, and assume the correct curvature. By eliminating the need for human donors, the material promises scalable manufacturing and lower price points.

Material scientist Shuo Li, whose family includes ophthalmologists, highlighted successful animal trials that demonstrated safe implantation and stable visual outcomes. He emphasized that the implant’s design was driven by the global 98 % donor‑tissue shortage.

If the upcoming pilot clinical study confirms safety and efficacy, the technology could shift keratoconus treatment from a transplant‑dependent model to an off‑the‑shelf solution, potentially restoring vision for millions and reshaping the ophthalmic device market.

Original Description

Millions of people around the world are affected by keratoconus, a progressive eye disorder where the cornea thins and bulges outwards. In severe cases, a corneal transplant may be the only treatment option; however, there is a limited supply of donor tissue.

The Augel project is set to change this. ETH Pioneer Fellow Shuo Li is developing a soft hydrogel implant to stabilise the cornea and improve vision. The implant can be manufactured entirely in the lab, is cost-effective and can be integrated with existing laser surgery methods.

Initial tests in the laboratory and in animal models have yielded promising results. The next step is to initiate the first human clinical study of the method.

Video: Nicole Davidson (video production), Helena Klein (animation) / ETH Zurich

ethz.ch https://ethz.ch/en.html

Instagram https://www.instagram.com/ethzurich/

TikTok https://www.tiktok.com/@ethzurich

LinkedIn https://www.linkedin.com/school/4923/

Bluesky https://bsky.app/profile/ethzurich.bsky.social/

Facebook http://www.facebook.com/eth